MGI Tech and NeoGenomica Expand Access to High-Throughput Genomics in Brazil
São Paulo, Brazil – MGI Tech Co., Ltd. (MGI), a company delicated to developing tools and technologies that drive innovation in life sciences, today announced a strategic partnership with NeoGenomica, a leading Brazilian laboratory specialising in advanced genetic testing. The collaboration aims to expand access to genomics applications in oncology, rare diseases, and precision medicine while supporting the development of Brazil’s scientific and innovation ecosystem.
In practical terms, the initiative enables patients with rare cancers to receive comprehensive genetic diagnoses in days rather than weeks, allowing physicians to begin the most effective treatments earlier, improving outcomes and quality of life.
Founded in 2024 and led by immunologist João Bosco Oliveira Filho, NeoGenomica aims to expand access to advanced genetic testing, support more precise clinical decision-making, and strengthen precision medicine as a strategic pillar of healthcare innovation in Brazil. With operations in Recife and São Paulo, the laboratory receives samples from across the country, reinforcing its national reach and logistical capacity.
“This level of speed is critical in situations where time is a determining factor,” said João Bosco Oliveira Filho, immunology specialist and founder of NeoGenomica. “For families awaiting a rare disease diagnosis in a new-born, or oncology patients whose treatment depends on a detailed genetic profile, reducing waiting time creates immeasurable value. It means faster access to personalised therapies, less anxiety, and ultimately a meaningful transformation in healthcare delivery.”
Cutting Edge Infrastructure at NeoGenomica
The newly installed infrastructure includes:
- DNBSEQ-T7 sequencer: one of the highest-throughput sequencing systems in the world
- Advanced automation: MGISP-960 and MGISP-100 systems for automated sample preparation
- Massive capacity: up to 7 terabytes of genomic data generated every 24 hours
- Direct clinical impact: greater efficiency and faster delivery of complex tests, including whole-genome sequencing, enabling large-scale high-throughput operations
Beyond its clinical capabilities, the partnership also includes education-focused initiatives such as technical training, scientific knowledge exchange, and support for the adoption of best practices in genomics and personalised medicine across Brazil.
Clinical Applications and Impact
Key applications include comprehensive genetic mapping used to identify disease-associated variants, guide therapeutic decisions, and support prevention strategies. These tests are primarily applied in oncology and rare diseases and are supported by advanced bioinformatics platforms capable of analysing large volumes of genetic data with high scientific rigour.
The partnership combines MGI’s technological leadership with NeoGenomica’s clinical and scientific expertise.
“This collaboration reinforces MGI’s strategy of investing in Brazil as a priority market for advancing genomics in healthcare,” said Carlos Carpio, Head of MGI for Latin America. “Our technology enables the scaling of complex tests with high precision, making precision medicine more accessible and sustainable. Together with NeoGenomica, we aim to support the continued growth of Brazil’s genomic industry.”
Genomics as a Catalyst for Healthcare Innovation
Genomics has become a central pillar of precision medicine and a key driver of healthcare transformation. By enabling faster diagnoses and personalised treatments, genomic technologies improve clinical efficiency, reduce costs associated with ineffective therapies, and increase the value delivered to patients.
“Genomics is one of the most powerful forces transforming healthcare today, directly improving diagnostic efficiency and treatment personalisation,” said João Bosco Oliveira Filho. “With MGI’s technology, we can operate at scale and with high data capacity, expanding access to advanced testing and strengthening Brazil’s innovation ecosystem. We are proud to lead this transformation from Pernambuco, building a centre of excellence that will serve the entire country.”
Through this collaboration, MGI and NeoGenomica reinforce Brazil’s position in the global biotechnology and healthcare innovation landscape, expanding access to high-value genomic technologies and accelerating data-driven models of care.
About NeoGenomica
NeoGenomica Laboratory, headquartered in Recife, is a national reference in advanced genetic analysis. Established in 2024, the centre aims to advance healthcare innovation through genetics by providing high-precision diagnostics that support prevention and personalised medicine.
Under the leadership of physician João Bosco Oliveira Filho, NeoGenomica works to expand access to advanced diagnostic technologies using Next-Generation Sequencing (NGS), one of the most powerful tools available for genetic testing worldwide.
Among its services, whole-genome sequencing enables the identification of disease predispositions, guides personalised therapies, and strengthens prevention strategies, supporting physicians and patients in more informed clinical decisions.
The laboratory operates with state-of-the-art equipment, including MGI’s DNBSEQ-T7 sequencer, capable of generating up to 7 TB of high-quality data in 24 hours and sequencing up to 54 whole genomes per day. Advanced bioinformatics platforms are used to analyse and interpret genetic data with high technical rigour.
Strategically located in Brazil’s Northeast, NeoGenomica receives samples from across the country, including remote states such as Amapá, reinforcing its national reach and logistical capacity. The laboratory represents an important milestone for healthcare innovation in Pernambuco and Brazil, positioning Recife as a growing hub for genetics and precision medicine.
